1
|
Beyer AK, Schlack R, Neuperdt L, Kuhnert R, Hölling H, Romanos M, Jans T, Berner A, Hetzke L, Weyrich S, Emser T, Hauer D, Scholz V, Ulsamer S, Wallau C, Ravens-Sieberer U, Kaman A, Gilbert M, Greiner W, Witte J, Seck K, Heuschmann PU, Fiessler C, Widmann J, Riederer C. Das Projekt INTEGRATE-ADHD: Vergleich und Integration administrativer
und epidemiologischer ADHS-Diagnosedaten durch klinisches Assessment bei Kindern
und Jugendlichen in Deutschland. Das Gesundheitswesen 2022. [DOI: 10.1055/s-0042-1753801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- A-K Beyer
- Robert Koch-Institut, Abteilung für Epidemiologie und
Gesundheitsmonitoring, Berlin, Deutschland
| | - R Schlack
- Robert Koch-Institut, Abteilung für Epidemiologie und
Gesundheitsmonitoring, Berlin, Deutschland
| | - L Neuperdt
- Robert Koch-Institut, Abteilung für Epidemiologie und
Gesundheitsmonitoring, Berlin, Deutschland
| | - R Kuhnert
- Robert Koch-Institut, Abteilung für Epidemiologie und
Gesundheitsmonitoring, Berlin, Deutschland
| | - H Hölling
- Robert Koch-Institut, Abteilung für Epidemiologie und
Gesundheitsmonitoring, Berlin, Deutschland
| | - M Romanos
- Universitätsklinikum Würzburg, Zentrum für
Psychische Gesundheit, Klinik und Poliklinik für Kinder- und
Jugendpsychiatrie, Psychosomatik und Psychotherapie, Würzburg,
Deutschland
| | - T Jans
- Universitätsklinikum Würzburg, Zentrum für
Psychische Gesundheit, Klinik und Poliklinik für Kinder- und
Jugendpsychiatrie, Psychosomatik und Psychotherapie, Würzburg,
Deutschland
| | - A Berner
- Universitätsklinikum Würzburg, Zentrum für
Psychische Gesundheit, Klinik und Poliklinik für Kinder- und
Jugendpsychiatrie, Psychosomatik und Psychotherapie, Würzburg,
Deutschland
| | - L Hetzke
- Universitätsklinikum Würzburg, Zentrum für
Psychische Gesundheit, Klinik und Poliklinik für Kinder- und
Jugendpsychiatrie, Psychosomatik und Psychotherapie, Würzburg,
Deutschland
| | - S Weyrich
- Universitätsklinikum Würzburg, Zentrum für
Psychische Gesundheit, Klinik und Poliklinik für Kinder- und
Jugendpsychiatrie, Psychosomatik und Psychotherapie, Würzburg,
Deutschland
| | - T Emser
- Universitätsklinikum Würzburg, Zentrum für
Psychische Gesundheit, Klinik und Poliklinik für Kinder- und
Jugendpsychiatrie, Psychosomatik und Psychotherapie, Würzburg,
Deutschland
| | - D Hauer
- Universitätsklinikum Würzburg, Zentrum für
Psychische Gesundheit, Klinik und Poliklinik für Kinder- und
Jugendpsychiatrie, Psychosomatik und Psychotherapie, Würzburg,
Deutschland
| | - V Scholz
- Universitätsklinikum Würzburg, Zentrum für
Psychische Gesundheit, Klinik und Poliklinik für Kinder- und
Jugendpsychiatrie, Psychosomatik und Psychotherapie, Würzburg,
Deutschland
- Radboud University, Donders Institute for Brain, Cognition and
Behaviour, Nijmegen, Niederlande
| | - S Ulsamer
- Universitätsklinikum Würzburg, Zentrum für
Psychische Gesundheit, Klinik und Poliklinik für Kinder- und
Jugendpsychiatrie, Psychosomatik und Psychotherapie, Würzburg,
Deutschland
| | - C Wallau
- Universitätsklinikum Würzburg, Zentrum für
Psychische Gesundheit, Klinik und Poliklinik für Kinder- und
Jugendpsychiatrie, Psychosomatik und Psychotherapie, Würzburg,
Deutschland
| | - U Ravens-Sieberer
- Universitätsklinikum Hamburg-Eppendorf, Klinik für
Kinder- und Jugendpsychiatrie, -psychotherapie und –psychosomatik,
Forschungssektion „Child Public Health", Hamburg,
Deutschland
| | - A Kaman
- Universitätsklinikum Hamburg-Eppendorf, Klinik für
Kinder- und Jugendpsychiatrie, -psychotherapie und –psychosomatik,
Forschungssektion „Child Public Health", Hamburg,
Deutschland
| | - M Gilbert
- Universitätsklinikum Hamburg-Eppendorf, Klinik für
Kinder- und Jugendpsychiatrie, -psychotherapie und –psychosomatik,
Forschungssektion „Child Public Health", Hamburg,
Deutschland
| | - W Greiner
- Universität Bielefeld, Lehrstuhl für
Gesundheitsökonomie und Gesundheitsmanagement, Bielefeld,
Deutschland
| | - J Witte
- Vandage GmbH, Bielefeld, Deutschland
| | - K Seck
- Vandage GmbH, Bielefeld, Deutschland
| | - PU Heuschmann
- Julius-Maximilians-Universität Würzburg, Institut
für Klinische Epidemiologie und Biometrie, Würzburg,
Deutschland
| | - C Fiessler
- Julius-Maximilians-Universität Würzburg, Institut
für Klinische Epidemiologie und Biometrie, Würzburg,
Deutschland
| | - J Widmann
- Julius-Maximilians-Universität Würzburg, Institut
für Klinische Epidemiologie und Biometrie, Würzburg,
Deutschland
| | | |
Collapse
|
2
|
Tini E, Smigielski L, Romanos M, Wewetzer C, Karwautz A, Reitzle K, Correll C, Plener P, Malzahn U, Heuschmann P, Unterecker S, Scherf-Clavel M, Rock H, Antony G, Briegel W, Fleischhaker C, Banaschewski T, Hellenschmidt T, Imgart H, Kaess M, Kölch M, Renner T, Reuter-Dang S, Rexroth C, Schulte-Körne G, Theisen F, Fekete S, Taurines R, Gerlach M, Egberts K, Walitza S. Therapeutic drug monitoring of sertraline in pediatric population: A
naturalistic study with insights into the clinical response of
obsessive-compulsive disorder. PHARMACOPSYCHIATRY 2022. [DOI: 10.1055/s-0042-1747663] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- E. Tini
- Department of Child and Adolescent Psychiatry and Psychotherapy,
Psychiatric University Hospital Zurich, University of Zurich, Zürich,
Switzerland
| | - L. Smigielski
- Department of Child and Adolescent Psychiatry and Psychotherapy,
Psychiatric University Hospital Zurich, University of Zurich, Zürich,
Switzerland
| | - M. Romanos
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg,
Wuerzburg, Germany
| | - C. Wewetzer
- Kliniken der Stadt Köln GmbH, Clinic for Child and Adolescent
Psychiatry Holweide, Children's Hospital Amsterdamer Straße,
Cologne, Germany
| | - A. Karwautz
- Department of Child and Adolescent Psychiatry, Medical University
Vienna, Vienna, Austria
| | - K. Reitzle
- Specialist practice and Medical Care Center for Child and Adolescent
Psychiatry Munich, Munich, Germany
| | - C.U. Correll
- Department of Child and Adolescent Psychiatry, Charité
Universitätsmedizin Berlin, Berlin, Germany
- The Zucker Hillside Hospital, Department of Psychiatry, Northwell
Health, Glen Oaks, NY, USA
- Donald and Barbara Zucker School of Medicine at
Hofstra/Northwell, Department of Psychiatry and Molecular Medicine,
Hempstead, NY, USA
| | - P.L. Plener
- Department of Child and Adolescent Psychiatry/Psychotherapy,
University Hospital Ulm, Ulm, Germany
- Department of Child and Adolescent Psychiatry, Medical University
Vienna, Vienna, Austria
| | - U. Malzahn
- Clinical Trial Center Wuerzburg, University Hospital Wuerzburg,
Wuerzburg, Germany
| | - P. Heuschmann
- Clinical Trial Center Wuerzburg, University Hospital Wuerzburg,
Wuerzburg, Germany
- Institute of Clinical Epidemiology and Biometry, University of
Wuerzburg, Germany
| | - S. Unterecker
- Department of Psychiatry, Psychosomatics and Psychotherapy, Center of
Mental Health, University Hospital Wuerzburg, Wuerzburg, Germany
| | - M. Scherf-Clavel
- Department of Psychiatry, Psychosomatics and Psychotherapy, Center of
Mental Health, University Hospital Wuerzburg, Wuerzburg, Germany
| | - H. Rock
- Central Information Office, Department of Neurology, Philipps
University of Marburg, Marburg, Germany
| | - G. Antony
- Central Information Office, Department of Neurology, Philipps
University of Marburg, Marburg, Germany
| | - W. Briegel
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg,
Wuerzburg, Germany
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Leopoldina Hospital, Schweinfurt, Germany
| | - C. Fleischhaker
- Department of Child and Adolescent Psychiatry and Psychotherapy,
University Medical Center Freiburg, Freiburg, Germany
| | - T. Banaschewski
- Department of Child and Adolescent Psychiatry and Psychotherapy,
Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg
University, Mannheim, Germany
| | - T. Hellenschmidt
- Department of Child and Adolescent Psychiatry, Psychotherapy and
Psychosomatic medicine, Vivantes Clinic Berlin Neukölln, Berlin,
Germany
| | - H. Imgart
- Parkland-Clinic, Clinic for Psychosomatics and Psychotherapy, academic
teaching hospital for the University Gießen, Bad Wildungen,
Germany
| | - M. Kaess
- Clinic for Child and Adolescent Psychiatry, Center for Psychosocial
Medicine, University Hospital Heidelberg, Heidelberg, Germany
- University Hospital of Child and Adolescent Psychiatry and
Psychotherapy, University of Bern, Bern, Switzerland
| | - M. Kölch
- Department of Child and Adolescent Psychiatry and Psychotherapy,
Brandenburg Medical School Brandenburg, Neuruppin, Germany
- Department of Child and Adolescent Psychiatry, Neurology,
Psychosomatics, and Psychotherapy, University Medical Center Rostock, Rostock,
Germany
| | - T. Renner
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, University Hospital of Psychiatry and Psychotherapy Tuebingen,
Center of Mental Health Tuebingen, Germany
| | - S.Y. Reuter-Dang
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg,
Wuerzburg, Germany
- Specialist practice and Medical Care Center for Child and Adolescent
Psychiatry Munich, Munich, Germany
| | - C. Rexroth
- Clinic for Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, University of Regensburg at the Regensburg District Hospital,
medbo KU, Regensburg, Germany
| | - G. Schulte-Körne
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Ludwig-Maximilians-University (LMU) Hospital, Munich,
Germany
| | - F. Theisen
- Department of Child and Adolescent Psychiatry and Psychotherapy,
Herz-Jesu-Krankenhaus gGmbH, Fulda, Germany
| | - S. Fekete
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg,
Wuerzburg, Germany
| | - R. Taurines
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg,
Wuerzburg, Germany
| | - M. Gerlach
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg,
Wuerzburg, Germany
| | - K.M. Egberts
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg,
Wuerzburg, Germany
| | - S. Walitza
- Department of Child and Adolescent Psychiatry and Psychotherapy,
Psychiatric University Hospital Zurich, University of Zurich, Zürich,
Switzerland
- Zurich Center for Integrative Human Physiology, University of Zurich,
Zürich, Switzerland
- Neuroscience Center Zurich, University of Zurich and ETH, Zurich,
Switzerland
| |
Collapse
|
3
|
Fekete S, Güntzel T, Egberts K, Geissler J, Neubert A, Gerlach M, Romanos M, Taurines R. Serious adverse drug reactions to antipsychotics in children and
adolescents with multiple disabilities: Avoidability and potential cost savings
by Therapeutic Drug Monitoring. PHARMACOPSYCHIATRY 2022. [DOI: 10.1055/s-0042-1747649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- S. Fekete
- University Hospital of Wuerzburg, Center of Mental Health, Department
of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Wuerzburg,
Germany
- AGNP-Work group ‘Child and Adolescent
Psychopharmacology’
| | - T. Güntzel
- University Hospital of Wuerzburg, Center of Mental Health, Department
of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Wuerzburg,
Germany
| | - K. Egberts
- University Hospital of Wuerzburg, Center of Mental Health, Department
of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Wuerzburg,
Germany
- AGNP-Work group ‘Child and Adolescent
Psychopharmacology’
- AGNP-Work group «Therapeutic Drug
Monitoring»
- Competence network for Therapeutic Drug Monitoring in child and
adolescent psychiatry
| | - J. Geissler
- University Hospital of Wuerzburg, Center of Mental Health, Department
of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Wuerzburg,
Germany
| | - A. Neubert
- Department of Experimental and Clinical Pharmacology and Toxicology,
Friedrich Alexander University Erlangen-Nuernberg, Erlangen,
Germany
| | - M. Gerlach
- University Hospital of Wuerzburg, Center of Mental Health, Department
of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Wuerzburg,
Germany
- AGNP-Work group ‘Child and Adolescent
Psychopharmacology’
- AGNP-Work group «Therapeutic Drug
Monitoring»
- Competence network for Therapeutic Drug Monitoring in child and
adolescent psychiatry
| | - M. Romanos
- University Hospital of Wuerzburg, Center of Mental Health, Department
of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Wuerzburg,
Germany
- AGNP-Work group ‘Child and Adolescent
Psychopharmacology’
- AGNP-Work group «Therapeutic Drug
Monitoring»
| | - R. Taurines
- University Hospital of Wuerzburg, Center of Mental Health, Department
of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Wuerzburg,
Germany
- AGNP-Work group «Therapeutic Drug
Monitoring»
| |
Collapse
|
4
|
Smigielski L, Tini E, Romanos M, Wewetzer C, Karwautz A, Reitzle K, Correll C, Plener P, Malzahn U, Heuschmann P, Unterecker S, Scherf-Clavel M, Rock H, Antony G, Briegel W, Fleischhaker C, Banaschewski T, Hellenschmidt T, Imgart H, Kaess M, Kölch M, Renner T, Reuter-Dang S, Rexroth C, Schulte-Körne G, Theisen F, Fekete S, Taurines R, Gerlach M, Egberts K, Walitza S. Therapeutic drug monitoring of mirtazapine in children and
adolescents: Analysis of dose, steady-state concentration and responsiveness in
a naturalistic clinical setting. PHARMACOPSYCHIATRY 2022. [DOI: 10.1055/s-0042-1747661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- L. Smigielski
- Department of Child and Adolescent Psychiatry and Psychotherapy,
Psychiatric University Hospital Zurich, University of Zurich, Zürich,
Switzerland
| | - E. Tini
- Department of Child and Adolescent Psychiatry and Psychotherapy,
Psychiatric University Hospital Zurich, University of Zurich, Zürich,
Switzerland
| | - M. Romanos
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg,
Wuerzburg, Germany
| | - C. Wewetzer
- Kliniken der Stadt Köln GmbH, Clinic for Child and Adolescent
Psychiatry Holweide, Children's Hospital Amsterdamer Straße,
Cologne, Germany
| | - A. Karwautz
- Department of Child and Adolescent Psychiatry, Medical University
Vienna, Vienna, Austria
| | - K. Reitzle
- Specialist practice and Medical Care Center for Child and Adolescent
Psychiatry Munich, Munich, Germany
| | - C.U. Correll
- Department of Child and Adolescent Psychiatry, Charité
Universitätsmedizin Berlin, Berlin, Germany
- The Zucker Hillside Hospital, Department of Psychiatry, Northwell
Health, Glen Oaks, NY, USA
- Donald and Barbara Zucker School of Medicine at
Hofstra/Northwell, Department of Psychiatry and Molecular Medicine,
Hempstead, NY, USA
| | - P.L. Plener
- Department of Child and Adolescent Psychiatry/Psychotherapy,
University Hospital Ulm, Ulm, Germany
- Department of Child and Adolescent Psychiatry, Medical University
Vienna, Vienna, Austria
| | - U. Malzahn
- Clinical Trial Center Wuerzburg, University Hospital Wuerzburg,
Wuerzburg, Germany
| | - P. Heuschmann
- Clinical Trial Center Wuerzburg, University Hospital Wuerzburg,
Wuerzburg, Germany
- Institute of Clinical Epidemiology and Biometry, University of
Wuerzburg, Germany
| | - S. Unterecker
- Department of Psychiatry, Psychosomatics and Psychotherapy, Center of
Mental Health, University Hospital Wuerzburg, Wuerzburg, Germany
| | - M. Scherf-Clavel
- Department of Psychiatry, Psychosomatics and Psychotherapy, Center of
Mental Health, University Hospital Wuerzburg, Wuerzburg, Germany
| | - H. Rock
- Central Information Office, Department of Neurology, Philipps
University of Marburg, Marburg, Germany
| | - G. Antony
- Central Information Office, Department of Neurology, Philipps
University of Marburg, Marburg, Germany
| | - W. Briegel
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg,
Wuerzburg, Germany
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Leopoldina Hospital, Schweinfurt, Germany
| | - C. Fleischhaker
- Department of Child and Adolescent Psychiatry and Psychotherapy,
University Medical Center Freiburg, Freiburg, Germany
| | - T. Banaschewski
- Department of Child and Adolescent Psychiatry and Psychotherapy,
Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg
University, Mannheim, Germany
| | - T. Hellenschmidt
- Department of Child and Adolescent Psychiatry, Psychotherapy and
Psychosomatic medicine, Vivantes Clinic Berlin Neukölln, Berlin,
Germany
| | - H. Imgart
- Parkland-Clinic, Clinic for Psychosomatics and Psychotherapy, academic
teaching hospital for the University Gießen, Bad Wildungen,
Germany
| | - M. Kaess
- Clinic for Child and Adolescent Psychiatry, Center for Psychosocial
Medicine, University Hospital Heidelberg, Heidelberg, Germany
- University Hospital of Child and Adolescent Psychiatry and
Psychotherapy, University of Bern, Bern, Switzerland
| | - M. Kölch
- Department of Child and Adolescent Psychiatry and Psychotherapy,
Brandenburg Medical School Brandenburg, Neuruppin, Germany
- Department of Child and Adolescent Psychiatry, Neurology,
Psychosomatics, and Psychotherapy, University Medical Center Rostock, Rostock,
Germany
| | - T. Renner
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, University Hospital of Psychiatry and Psychotherapy Tuebingen,
Center of Mental Health Tuebingen, Germany
| | - S.Y. Reuter-Dang
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg,
Wuerzburg, Germany
- Specialist practice and Medical Care Center for Child and Adolescent
Psychiatry Munich, Munich, Germany
| | - C. Rexroth
- Clinic for Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, University of Regensburg at the Regensburg District Hospital,
medbo KU, Regensburg, Germany
| | - G. Schulte-Körne
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Ludwig-Maximilians-University (LMU) Hospital, Munich,
Germany
| | - F. Theisen
- Department of Child and Adolescent Psychiatry and Psychotherapy,
Herz-Jesu-Krankenhaus gGmbH, Fulda, Germany
| | - S. Fekete
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg,
Wuerzburg, Germany
| | - R. Taurines
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg,
Wuerzburg, Germany
| | - M. Gerlach
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg,
Wuerzburg, Germany
| | - K.M. Egberts
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg,
Wuerzburg, Germany
| | - S. Walitza
- Department of Child and Adolescent Psychiatry and Psychotherapy,
Psychiatric University Hospital Zurich, University of Zurich, Zürich,
Switzerland
- Zurich Center for Integrative Human Physiology, University of Zurich,
Zürich, Switzerland
- Neuroscience Center Zurich, University of Zurich and ETH, Zurich,
Switzerland
| |
Collapse
|
5
|
Taurines R, Fekete S, Preuss-Wiedenhoff A, Warnke A, Wewetzer C, Plener P, Burger R, Gerlach M, Romanos M, Egberts KM. Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone. J Neural Transm (Vienna) 2022; 129:689-701. [PMID: 35303169 PMCID: PMC9188514 DOI: 10.1007/s00702-022-02485-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2022] [Accepted: 02/24/2022] [Indexed: 01/31/2023]
Abstract
Risperidone is commonly used to treat different psychiatric disorders worldwide. Knowledge on dose–concentration relationships of risperidone treatment in children and adolescents with schizophrenia or other psychotic disorders is, however, scarce and no age-specific therapeutic ranges have been established yet. Multicenter data of a therapeutic drug monitoring service were analyzed to evaluate the relationship between risperidone dose and serum concentration of the active moiety (risperidone (RIS) plus its main metabolite 9-hydroxyrisperidone (9-OH-RIS)) in children and adolescents with psychotic disorders. Patient characteristics, doses, serum concentrations and therapeutic outcomes were assessed by standardized measures. The study also aimed to evaluate whether the therapeutic reference range for adults (20–60 ng/ml) is applicable for minors. In the 64 patients (aged 11–18 years) included, a positive correlation between daily dose and the active moiety (RISam) concentration was found (rs = 0.49, p = 0.001) with variation in dose explaining 24% (rs2 = 0.240) of the variability in serum concentrations. While the RISam concentration showed no difference, RIS as well 9-OH-RIS concentrations and the parent to metabolite ratio varied significantly in patients with co-medication of a CYP2D6 inhibitor. Patients with extrapyramidal symptoms (EPS) had on average higher RISam concentrations than patients without (p = 0.05). Considering EPS, the upper threshold of the therapeutic range of RISam was determined to be 33 ng/ml. A rough estimation method also indicated a possibly decreased lower limit of the preliminary therapeutic range in minors compared to adults. These preliminary data may contribute to the definition of a therapeutic window in children and adolescents with schizophrenic disorders treated with risperidone. TDM is recommended in this vulnerable population to prevent concentration-related adverse drug reactions.
Collapse
Affiliation(s)
- R Taurines
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg, Margarete-Hoeppel-Platz 1, 97080, Wuerzburg, Germany
| | - S Fekete
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg, Margarete-Hoeppel-Platz 1, 97080, Wuerzburg, Germany
| | - A Preuss-Wiedenhoff
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg, Margarete-Hoeppel-Platz 1, 97080, Wuerzburg, Germany
| | - A Warnke
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg, Margarete-Hoeppel-Platz 1, 97080, Wuerzburg, Germany
| | - C Wewetzer
- Clinic for Child and Adolescent Psychiatry and Psychotherapy, Clinics of the City Cologne GmbH, Cologne, Germany
| | - P Plener
- Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Ulm, Ulm, Germany.,Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna, Austria
| | - R Burger
- Department of Psychiatry, Psychosomatics and Psychotherapy, Laboratory for Therapeutic Drug Monitoring, Centre for Mental Health, University Hospital of Wuerzburg, Wuerzburg, Germany
| | - M Gerlach
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg, Margarete-Hoeppel-Platz 1, 97080, Wuerzburg, Germany
| | - M Romanos
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg, Margarete-Hoeppel-Platz 1, 97080, Wuerzburg, Germany
| | - K M Egberts
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg, Margarete-Hoeppel-Platz 1, 97080, Wuerzburg, Germany.
| |
Collapse
|
6
|
Fekete S, Egberts K, Preissler T, Wewetzer C, Mehler-Wex C, Romanos M, Gerlach M. Correction to: Estimation of a preliminary therapeutic reference range for children and adolescents with tic disorders treated with tiapride. Eur J Clin Pharmacol 2021; 77:1257. [PMID: 34047799 PMCID: PMC8496611 DOI: 10.1007/s00228-021-03159-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- Stefanie Fekete
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Centre for Mental Health, University Hospital of Würzburg, Margarete-Höppel-Platz 1, 97080, Würzburg, Germany.
- Arbeitsgemeinschaft Für Neuropsychopharmakologie Und Pharmakopsychiatrie (AGNP)-Work Group "Kinder- Und Jugendpsychiatrische Pharmakologie", Psychotherapie Und Psychosomatik, Kliniken Für Kinder- Und Jugendpsychiatrie, Vivantes Klinikum Im Friedrichshain, 1. Vorsitzender Prof. Dr. med. M. KölchVivantes Klinikum Neukölln, Landsberger Allee 49, 10249, Berlin, Germany.
| | - K Egberts
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Centre for Mental Health, University Hospital of Würzburg, Margarete-Höppel-Platz 1, 97080, Würzburg, Germany
- Arbeitsgemeinschaft Für Neuropsychopharmakologie Und Pharmakopsychiatrie (AGNP)-Work Group "Kinder- Und Jugendpsychiatrische Pharmakologie", Psychotherapie Und Psychosomatik, Kliniken Für Kinder- Und Jugendpsychiatrie, Vivantes Klinikum Im Friedrichshain, 1. Vorsitzender Prof. Dr. med. M. KölchVivantes Klinikum Neukölln, Landsberger Allee 49, 10249, Berlin, Germany
- Competence Network Therapeutic Drug Monitoring (TDM-KJP E.V.), Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Centre forMental Health, University Hospital ofWürzburg, Margarete-Höppel-Platz 1, 97080, Würzburg, Germany
| | - T Preissler
- Department of Child and Adolescent Psychiatry and Psychotherapy, Kepler University Clinics GmbH, Linz, Austria
| | - C Wewetzer
- Clinic for Child and Adolescent Psychiatry and Psychotherapy, Clinics of the City Cologne GmbH, Cologne, Germany
| | - C Mehler-Wex
- Arbeitsgemeinschaft Für Neuropsychopharmakologie Und Pharmakopsychiatrie (AGNP)-Work Group "Kinder- Und Jugendpsychiatrische Pharmakologie", Psychotherapie Und Psychosomatik, Kliniken Für Kinder- Und Jugendpsychiatrie, Vivantes Klinikum Im Friedrichshain, 1. Vorsitzender Prof. Dr. med. M. KölchVivantes Klinikum Neukölln, Landsberger Allee 49, 10249, Berlin, Germany
- Competence Network Therapeutic Drug Monitoring (TDM-KJP E.V.), Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Centre forMental Health, University Hospital ofWürzburg, Margarete-Höppel-Platz 1, 97080, Würzburg, Germany
- Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Ulm, Ulm, Germany
- HEMERA Private Hospital for Mental Health, Adolescents and Young Adults, Bad Kissingen, Germany
| | - M Romanos
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Centre for Mental Health, University Hospital of Würzburg, Margarete-Höppel-Platz 1, 97080, Würzburg, Germany
- Arbeitsgemeinschaft Für Neuropsychopharmakologie Und Pharmakopsychiatrie (AGNP)-Work Group "Kinder- Und Jugendpsychiatrische Pharmakologie", Psychotherapie Und Psychosomatik, Kliniken Für Kinder- Und Jugendpsychiatrie, Vivantes Klinikum Im Friedrichshain, 1. Vorsitzender Prof. Dr. med. M. KölchVivantes Klinikum Neukölln, Landsberger Allee 49, 10249, Berlin, Germany
- Competence Network Therapeutic Drug Monitoring (TDM-KJP E.V.), Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Centre forMental Health, University Hospital ofWürzburg, Margarete-Höppel-Platz 1, 97080, Würzburg, Germany
| | - M Gerlach
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Centre for Mental Health, University Hospital of Würzburg, Margarete-Höppel-Platz 1, 97080, Würzburg, Germany
- Arbeitsgemeinschaft Für Neuropsychopharmakologie Und Pharmakopsychiatrie (AGNP)-Work Group "Kinder- Und Jugendpsychiatrische Pharmakologie", Psychotherapie Und Psychosomatik, Kliniken Für Kinder- Und Jugendpsychiatrie, Vivantes Klinikum Im Friedrichshain, 1. Vorsitzender Prof. Dr. med. M. KölchVivantes Klinikum Neukölln, Landsberger Allee 49, 10249, Berlin, Germany
- Competence Network Therapeutic Drug Monitoring (TDM-KJP E.V.), Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Centre forMental Health, University Hospital ofWürzburg, Margarete-Höppel-Platz 1, 97080, Würzburg, Germany
| |
Collapse
|
7
|
Egberts K, Plener P, Fekete S, Taurines R, Gerlach M, Romanos M. 6 A multicenter pharmacovigilance study on antidepressant and antipsychotic use in children and adolescents in daily clinical practice. PHARMACOPSYCHIATRY 2020. [DOI: 10.1055/s-0040-1710114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- K Egberts
- Department of child and adolescent psychiatry, University Hospital Wuerzburg
| | - P Plener
- Department of Child and Adolescent Psychiatry, Medical University Vienna
| | - S Fekete
- Department of child and adolescent psychiatry, University Hospital Wuerzburg
| | - R Taurines
- Department of child and adolescent psychiatry, University Hospital Wuerzburg
| | - M Gerlach
- Department of child and adolescent psychiatry, University Hospital Wuerzburg
| | - M Romanos
- Department of child and adolescent psychiatry, University Hospital Wuerzburg
| | | |
Collapse
|
8
|
Fekete S, Scherf-Clavel M, Gerlach M, Romanos M, Kittel-Schneider S, Unterecker S, Egberts K. 8 Serum concentrations of venlafaxine and risperidone and their metabolites from childhood to old age. PHARMACOPSYCHIATRY 2020. [DOI: 10.1055/s-0040-1710116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- S Fekete
- Department Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Center of Mental Health, University Hospital of Wuerzburg
| | - M Scherf-Clavel
- Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Center of Mental Health, University Hospital of Würzburg
| | - M Gerlach
- Department Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Center of Mental Health, University Hospital of Wuerzburg
| | - M Romanos
- Department Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Center of Mental Health, University Hospital of Wuerzburg
| | - S Kittel-Schneider
- Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Center of Mental Health, University Hospital of Würzburg
| | - S Unterecker
- Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Center of Mental Health, University Hospital of Würzburg
| | - K Egberts
- Department Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Center of Mental Health, University Hospital of Wuerzburg
| |
Collapse
|
9
|
Hacke M, Signoret-Genest J, Tovote P, Romanos M. Definition, detection and differentiation of acute emotional states using heart rate recording. PHARMACOPSYCHIATRY 2020. [DOI: 10.1055/s-0039-3403003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- M Hacke
- Klinik und Poliklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Universitätsklinikum Würzburg
- Institut für klinische Neurobiologie, Universitätsklinikum Würzburg
| | | | - P Tovote
- Institut für klinische Neurobiologie, Universitätsklinikum Würzburg
| | - M Romanos
- Klinik und Poliklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Universitätsklinikum Würzburg
| |
Collapse
|
10
|
Drepper C, Lüffe T, Romanos M, Lillesaar C. Loss-of-function of foxp2 in zebrafish larvae leads to behavioural changes resembling ADHD-like pathology. PHARMACOPSYCHIATRY 2020. [DOI: 10.1055/s-0039-3402988] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- C Drepper
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - T Lüffe
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - M Romanos
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - C Lillesaar
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| |
Collapse
|
11
|
Fekete S, Scherf-Clavel M, Gerlach M, Romanos M, Deckert J, Menke A, Egberts K, Unterecker S. Investigation of metabolite to parent compound ratios of venlafaxine and risperidone in minors. PHARMACOPSYCHIATRY 2020. [DOI: 10.1055/s-0039-3403046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- S Fekete
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - M Scherf-Clavel
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - M Gerlach
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - M Romanos
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - J Deckert
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - A Menke
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - K Egberts
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - S Unterecker
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| |
Collapse
|
12
|
Lüffe T, DʼOrazio A, Romanos M, Drepper C, Lillesaar C. GRM8, the role of a metabotropic glutamate receptor in ADHD. PHARMACOPSYCHIATRY 2020. [DOI: 10.1055/s-0039-3402984] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- T Lüffe
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - A DʼOrazio
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - M Romanos
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - C Drepper
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - C Lillesaar
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| |
Collapse
|
13
|
Radtke F, Holweck J, Geissler J, Strork T, Drepper C, Fouskova Z, Gerlach M, Fischer M, Romanos M. Olfactory function, transcranial sonography and fear generalization in patients with 22q11.2 deletion syndrome along the lifespan. PHARMACOPSYCHIATRY 2020. [DOI: 10.1055/s-0039-3402995] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- F Radtke
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - J Holweck
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - J Geissler
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - T Strork
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - C Drepper
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - Z Fouskova
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - M Gerlach
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - M Fischer
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - M Romanos
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| |
Collapse
|
14
|
Mühlberger A, Jekel K, Probst T, Schecklmann M, Conzelmann A, Andreatta M, Rizzo AA, Pauli P, Romanos M. The Influence of Methylphenidate on Hyperactivity and Attention Deficits in Children With ADHD: A Virtual Classroom Test. J Atten Disord 2020; 24:277-289. [PMID: 27178061 DOI: 10.1177/1087054716647480] [Citation(s) in RCA: 33] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Objective: This study compares the performance in a continuous performance test within a virtual reality classroom (CPT-VRC) between medicated children with ADHD, unmedicated children with ADHD, and healthy children. Method:N = 94 children with ADHD (n = 26 of them received methylphenidate and n = 68 were unmedicated) and n = 34 healthy children performed the CPT-VRC. Omission errors, reaction time/variability, commission errors, and body movements were assessed. Furthermore, ADHD questionnaires were administered and compared with the CPT-VRC measures. Results: The unmedicated ADHD group exhibited more omission errors and showed slower reaction times than the healthy group. Reaction time variability was higher in the unmedicated ADHD group compared with both the healthy and the medicated ADHD group. Omission errors and reaction time variability were associated with inattentiveness ratings of experimenters. Head movements were correlated with hyperactivity ratings of parents and experimenters. Conclusion: Virtual reality is a promising technology to assess ADHD symptoms in an ecologically valid environment.
Collapse
Affiliation(s)
- A Mühlberger
- University of Regensburg, Germany.,University of Würzburg, Germany
| | - K Jekel
- Heidelberg University, Germany
| | - T Probst
- University of Regensburg, Germany
| | | | - A Conzelmann
- University of Würzburg, Germany.,University of Tübingen, Germany
| | | | - A A Rizzo
- University of Southern California, Los Angeles, CA, USA
| | - P Pauli
- University of Würzburg, Germany
| | - M Romanos
- University Hospital of Würzburg, Germany
| |
Collapse
|
15
|
Stegmann Y, Schiele MA, Schümann D, Lonsdorf TB, Zwanzger P, Romanos M, Reif A, Domschke K, Deckert J, Gamer M, Pauli P. Individual differences in human fear generalization-pattern identification and implications for anxiety disorders. Transl Psychiatry 2019; 9:307. [PMID: 31740663 PMCID: PMC6861247 DOI: 10.1038/s41398-019-0646-8] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/05/2019] [Revised: 07/01/2019] [Accepted: 08/11/2019] [Indexed: 01/29/2023] Open
Abstract
Previous research indicates that anxiety disorders are characterized by an overgeneralization of conditioned fear as compared with healthy participants. Therefore, fear generalization is considered a key mechanism for the development of anxiety disorders. However, systematic investigations on the variance in fear generalization are lacking. Therefore, the current study aims at identifying distinctive phenotypes of fear generalization among healthy participants. To this end, 1175 participants completed a differential fear conditioning phase followed by a generalization test. To identify patterns of fear generalization, we used a k-means clustering algorithm based on individual arousal generalization gradients. Subsequently, we examined the reliability and validity of the clusters and phenotypical differences between subgroups on the basis of psychometric data and markers of fear expression. Cluster analysis reliably revealed five clusters that systematically differed in mean responses, differentiation between conditioned threat and safety, and linearity of the generalization gradients, though mean response levels accounted for most variance. Remarkably, the patterns of mean responses were already evident during fear acquisition and corresponded most closely to psychometric measures of anxiety traits. The identified clusters reliably described subgroups of healthy individuals with distinct response characteristics in a fear generalization test. Following a dimensional view of psychopathology, these clusters likely delineate risk factors for anxiety disorders. As crucial group characteristics were already evident during fear acquisition, our results emphasize the importance of average fear responses and differentiation between conditioned threat and safety as risk factors for anxiety disorders.
Collapse
Affiliation(s)
- Y Stegmann
- Department of Psychology, University of Würzburg, Würzburg, Germany
- Center for Mental Health, University of Würzburg, Würzburg, Germany
| | - M A Schiele
- Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - D Schümann
- Department of Systems Neuroscience, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - T B Lonsdorf
- Department of Systems Neuroscience, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - P Zwanzger
- kbo-Inn-Salzach-Hospital, Wasserburg, Germany
- Department of Psychiatry, University of Münster, Münster, Germany
- Department of Psychiatry, Ludwig-Maximilian-University of Munich, München, Germany
| | - M Romanos
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center for Mental Health, University Hospital Würzburg, Würzburg, Germany
| | - A Reif
- Center for Mental Health, University of Würzburg, Würzburg, Germany
- Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - K Domschke
- Center for Mental Health, University of Würzburg, Würzburg, Germany
- Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
- Center for NeuroModulation, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - J Deckert
- Department of Psychiatry, Psychosomatics and Psychotherapy, Center for Mental Health, University Hospital Würzburg, Würzburg, Germany
| | - M Gamer
- Department of Psychology, University of Würzburg, Würzburg, Germany
- Center for Mental Health, University of Würzburg, Würzburg, Germany
| | - P Pauli
- Department of Psychology, University of Würzburg, Würzburg, Germany.
- Center for Mental Health, University of Würzburg, Würzburg, Germany.
| |
Collapse
|
16
|
Wohkittel C, Romanos M, Högger P, Gerlach M. Influence of saliva pH-value on the ratio of amphetamine saliva to serum concentration. PHARMACOPSYCHIATRY 2018. [DOI: 10.1055/s-0038-1649542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- C Wohkittel
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Centre for Mental Health, University Hospital of Würzburg, Würzburg, Germany
| | - M Romanos
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Centre for Mental Health, University Hospital of Würzburg, Würzburg, Germany
| | - P Högger
- Institute of Pharmacy and Food Chemistry, University of Würzburg, Würzburg, Germany
| | - M Gerlach
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Centre for Mental Health, University Hospital of Würzburg, Würzburg, Germany
| |
Collapse
|
17
|
Egberts K, Dang SY, Plener P, Karwautz A, Taurines R, Romanos M, Gerlach M. Therapeutic Drug Monitoring in children and adolescents – looking 10 years back and forward. PHARMACOPSYCHIATRY 2018. [DOI: 10.1055/s-0038-1649528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- K Egberts
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Wuerzburg, Germany
- Competence Network Therapeutic Drug Monitoring (TDM-KJP) e.V
| | - SY Dang
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Wuerzburg, Germany
| | - P Plener
- Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Ulm, Ulm, Germany
- Department of Child and Adolescent Psychiatry, Medical University Vienna, Vienna, Austria
- Competence Network Therapeutic Drug Monitoring (TDM-KJP) e.V
| | - A Karwautz
- Department of Child and Adolescent Psychiatry, Medical University Vienna, Vienna, Austria
- Competence Network Therapeutic Drug Monitoring (TDM-KJP) e.V
| | - R Taurines
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Wuerzburg, Germany
- Competence Network Therapeutic Drug Monitoring (TDM-KJP) e.V
| | - M Romanos
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Wuerzburg, Germany
- Competence Network Therapeutic Drug Monitoring (TDM-KJP) e.V
| | - M Gerlach
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Wuerzburg, Germany
- Competence Network Therapeutic Drug Monitoring (TDM-KJP) e.V
| |
Collapse
|
18
|
Fekete S, Egberts K, Preissler T, Wewetzer C, Mehler-Wex C, Romanos M, Gerlach M. Therapeutic Drug Monitoring (TDM) of children and adolescents with tic disorders treated with tiapride. PHARMACOPSYCHIATRY 2017. [DOI: 10.1055/s-0037-1606421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- S Fekete
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Würzburg Centre for Mental Healt, Würzburg, Germany
| | - K Egberts
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Würzburg Centre for Mental Healt, Würzburg, Germany
| | - T Preissler
- Department of Child and Adolescent Psychiatry and Psychotherapy, Kepler University Clinics GmbH, Linz, Austria
| | - C Wewetzer
- Child and Adolescent Psychiatry and Psychotherapy, Clinics of City Cologne GmbH, Cologne, Germany
| | - C Mehler-Wex
- Adolescents and Young Adults, Hemera Private Hospital for Mental Health, Bad Kissingen, Germany
| | - M Romanos
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Würzburg Centre for Mental Healt, Würzburg, Germany
| | - M Gerlach
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Würzburg Centre for Mental Healt, Würzburg, Germany
| |
Collapse
|
19
|
Neufang S, Akhrif A, Herrmann CG, Drepper C, Homola GA, Nowak J, Waider J, Schmitt AG, Lesch KP, Romanos M. Serotonergic modulation of 'waiting impulsivity' is mediated by the impulsivity phenotype in humans. Transl Psychiatry 2016; 6:e940. [PMID: 27824354 PMCID: PMC5314122 DOI: 10.1038/tp.2016.210] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/18/2016] [Revised: 08/04/2016] [Accepted: 09/12/2016] [Indexed: 11/09/2022] Open
Abstract
In rodents, the five-choice serial reaction time task (5-CSRTT) has been established as a reliable measure of waiting impulsivity being defined as the ability to regulate a response in anticipation of reinforcement. Key brain structures are the nucleus accumbens (NAcc) and prefrontal regions (for example, pre- and infralimbic cortex), which are, together with other transmitters, modulated by serotonin. In this functional magnetic resonance imaging study, we examined 103 healthy males while performing the 5-CSRTT measuring brain activation in humans by means of a paradigm that has been widely applied in rodents. Subjects were genotyped for the tryptophan hydroxylase-2 (TPH2; G-703T; rs4570625) variant, an enzyme specific for brain serotonin synthesis. We addressed neural activation patterns of waiting impulsivity and the interaction between the NAcc and the ventromedial prefrontal cortex (vmPFC) using dynamic causal modeling. Genetic influence was examined via interaction analyses between the TPH2 genotype (GG homozygotes vs T allele carriers) and the degree of impulsivity as measured by the 5-CSRTT. We found that the driving input of the vmPFC was reduced in highly impulsive T allele carriers (reflecting a reduced top-down control) in combination with an enhanced response in the NAcc after correct target processing (reflecting an augmented response to monetary reward). Taken together, we found a high overlap of our findings with reports from animal studies in regard to the underlying cognitive processes, the brain regions associated with waiting impulsivity and the neural interplay between the NAcc and vmPFC. Therefore, we conclude that the 5-CSRTT is a promising tool for translational studies.
Collapse
Affiliation(s)
- S Neufang
- Center of Mental Health, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Wuerzburg, Germany,Center of Mental Health, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Fuechsleinstrasse 15, Wuerzburg D-97080, Germany. E-mail:
| | - A Akhrif
- Center of Mental Health, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Wuerzburg, Germany
| | - C G Herrmann
- Center of Mental Health, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Wuerzburg, Germany
| | - C Drepper
- Center of Mental Health, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Wuerzburg, Germany
| | - G A Homola
- Department of Neuroradiology, University of Wuerzburg, Wuerzburg, Germany
| | - J Nowak
- Department of Neuroradiology, University of Wuerzburg, Wuerzburg, Germany,Department of Radiology, University of Wuerzburg, Wuerzburg, Germany
| | - J Waider
- Center of Mental Health, Division of Molecular Psychiatry, Department of Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Wuerzburg, Germany
| | - A G Schmitt
- Center of Mental Health, Department of Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Wuerzburg, Germany
| | - K-P Lesch
- Center of Mental Health, Division of Molecular Psychiatry, Department of Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Wuerzburg, Germany
| | - M Romanos
- Center of Mental Health, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Wuerzburg, Germany
| |
Collapse
|
20
|
Norotte C, Omnès C, Crozier C, Verlyck C, Romanos M. [Crisis unit at the general hospital: Determinants of further hospitalization]. Encephale 2016; 43:444-450. [PMID: 27745725 DOI: 10.1016/j.encep.2016.08.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2014] [Accepted: 02/02/2016] [Indexed: 10/20/2022]
Abstract
INTRODUCTION The availability of short-stay beds for brief admission (less than 72hours) of crisis patients presenting to the emergency room is a model that has gained a growing interest because it allows time for developing alternatives to psychiatric hospitalization and favors a maintained functioning in the community. Still, the determinants influencing the disposition decision at discharge after crisis intervention remain largely unexplored. OBJECTIVE The primary objective of this study was to determine the factors predicting aftercare dispositions at crisis unit discharge: transfer for further hospitalization or return to the community. Secondary objectives included the description of clinical and socio-demographic characteristics of patients admitted to the crisis unit upon presentation to the emergency room. METHOD All patients (n=255) admitted to the short-stay unit of the emergency department of Rambouillet General Hospital during a one-year period were included in the study. Patient characteristics were collected in a retrospective manner from medical records: patterns of referral, acute stressors, presenting symptoms, initial patient demand, Diagnostic and Statistical Manual, 5th edition (DSM-5) disorders, psychiatric history, and socio-demographic characteristics were inferred. Logistic regression analysis was used to determine the factors associated with hospitalization decision upon crisis intervention at discharge. RESULTS Following crisis intervention at the short-stay unit, 100 patients (39.2%) required further hospitalization and were transferred. Statistically significant factors associated with a higher probability of hospitalization (P<0.05) included the patient's initial wish to be hospitalized (OR=4.28), the presence of a comorbid disorder (OR=3.43), a referral by family or friends (OR=2.89), a history of psychiatric hospitalization (OR=2.71) and suicidal ideation on arrival in the emergency room (OR=2.26). Conversely, significant factors associated with a lower probability of hospitalization were the presence of a personality disorder (OR=0.31), a precipitating conflict situation (OR=0.41), age between 20 and 39 years (OR=0.42), being employed (OR=0.49). CONCLUSION Our study confirms that clinical factors such as the presence of a personality disorder or the context of a precipitating conflict situation are predictive of a community return. Interestingly, it points out the importance of the patient's initial wish in the hospitalization decision.
Collapse
Affiliation(s)
- C Norotte
- Université Paris-Descartes, UFR de médecine, 75006 Paris, France.
| | - C Omnès
- Pôle de psychiatrie adultes 78G16, centre hospitalier Jean-Martin-Charcot, 78370 Plaisir, France
| | - C Crozier
- Département d'information médicale, centre hospitalier Jean-Martin-Charcot, 78370 Plaisir, France
| | - C Verlyck
- Pôle de psychiatrie adultes 78G16, centre hospitalier Jean-Martin-Charcot, 78370 Plaisir, France; Unité des urgences psychiatriques, centre hospitalier Général-de-Rambouillet, 78120 Plaisir, France
| | - M Romanos
- Pôle de psychiatrie adultes 78G16, centre hospitalier Jean-Martin-Charcot, 78370 Plaisir, France; Unité des urgences psychiatriques, centre hospitalier Général-de-Rambouillet, 78120 Plaisir, France
| |
Collapse
|
21
|
Romanos M, Coghill D, Gerlach M, Becker K, Holtmann M, Döpfner M, Banaschewski T. Check and Double Check – the Cochrane review by Storebo et al. (2015) is indeed flawed. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie 2016; 44:336-337. [DOI: 10.1024/1422-4917/a000473] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- M. Romanos
- Zentrum für Psychische Gesundheit, Klinik für Kinder-und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Universitätsklinikum Würzburg
| | - D. Coghill
- Departments of Paediatrics and Psychiatry, University of Melbourne, Melbourne, Australia
| | - M. Gerlach
- Zentrum für Psychische Gesundheit, Klinik für Kinder-und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Universitätsklinikum Würzburg
| | - K. Becker
- Klinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Universitätsklinikum Gießen und Marburg
| | - M. Holtmann
- Klinik für Kinder- und Jugendpsychiatrie, Psychotherapie und Psychosomatik, LWL-Universtitätsklinik Hamm der Ruhr-Universität Bochum
| | - M. Döpfner
- Ausbildungsinstitut für Kinder- und Jugendlichenpsychotherapie (AKiP) am Klinikum der Universität zu Köln
- Medizinische Fakultät, Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie des Kindes- und Jugendalters, Universität zu Köln
| | - T. Banaschewski
- Zentralinstitut für Seelische Gesundheit Mannheim, Klinik für Psychiatrie und Psychotherapie des Kindes-und Jugendalters (KJP)
| |
Collapse
|
22
|
Banaschewski T, Gerlach M, Becker K, Holtmann M, Döpfner M, Romanos M. Trust, but verify. The errors and misinterpretations in the Cochrane analysis by O. J. Storebo and colleagues on the efficacy and safety of methylphenidate for the treatment of children and adolescents with ADHD. Z Kinder Jugendpsychiatr Psychother 2016; 44:307-14. [PMID: 27270192 DOI: 10.1024/1422-4917/a000433] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Objective A recent Cochrane review published by O. J. Storebo and colleagues (2015) raised substantial doubts about the benefit from stimulant medication with methylphenidate in the treatment of childhood ADHD due to the overall poor quality of studies. The systematic review thus contradicts all previous reviews and meta-analyses. Method We here detail various examples of errors, inconsistencies, and misinterpretations in the review which led to false results and inadequate conclusions. Results We demonstrate that the study selection is flawed and undertaken without sufficient scientific justification resulting in an underestimation of effect sizes, which, furthermore, are inadmissibly clinically interpreted. The methodology of the assessment of bias and quality is not objective and cannot be substantiated by the data. Conclusions Cochrane reviews lay claim to a high scientific quality and substantial relevance for evidence-based clinical decisions. The systematic review by Storebo and colleagues (2015) illustrates that, despite adhering to strict standards and high-quality protocols, even Cochrane works should be critically read and verified, sometimes with surprising results.
Collapse
Affiliation(s)
- T Banaschewski
- 1 Zentralinstitut für Seelische Gesundheit Mannheim, Klinik für Psychiatrie und Psychotherapie des Kindes- und Jugendalters (KJP)
| | - M Gerlach
- 2 Zentrum für Psychische Gesundheit, Klinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Universitätsklinikum Würzburg
| | - K Becker
- 3 Klinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Universitätsklinikum Gießen und Marburg
| | - M Holtmann
- 4 Klinik für Kinder- und Jugendpsychiatrie, Psychotherapie und Psychosomatik, LWL-Universtitätsklinik Hamm der Ruhr-Universität Bochum
| | - M Döpfner
- 5 Ausbildungsinstitut für Kinder- und Jugendlichenpsychotherapie (AKiP) am Klinikum der Universität zu Köln.,6 Medizinische Fakultät, Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie des Kindes- und Jugendalters, Universität zu Köln
| | - M Romanos
- 2 Zentrum für Psychische Gesundheit, Klinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Universitätsklinikum Würzburg
| |
Collapse
|
23
|
Egberts K, Dang SY, Fekete S, Wohkittel C, Albantakis L, Mehler-Wex M, Plener P, Wewetzer C, Romanos M, Gerlach M. Therapeutic Drug Monitoring in Children and Adolescents Treated with Second-Generation Antipsychotics in Daily Clinical Practice. Pharmacopsychiatry 2016. [DOI: 10.1055/s-0036-1582027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
24
|
Kittel-Schneider S, Spiegel S, Renner T, Romanos M, Reif A, Reichert S, Heupel J, Schnetzler L, Stopper H, Jacob C. Cytogenetic Effects of Chronic Methylphenidate Treatment and Chronic Social Stress in Adults with Attention-Deficit/Hyperactivity Disorder. Pharmacopsychiatry 2016; 49:146-54. [DOI: 10.1055/s-0035-1569361] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
- S. Kittel-Schneider
- Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital of Frankfurt, Frankfurt, Germany
| | - S. Spiegel
- Institute of Toxikology, University of Würzburg, Würzburg, Germany
| | - T. Renner
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Tübingen, Tübingen, Germany
| | - M. Romanos
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Würzburg, Würzburg, Germany
| | - A. Reif
- Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital of Frankfurt, Frankfurt, Germany
| | - S. Reichert
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Würzburg, Würzburg, Germany
| | - J. Heupel
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Würzburg, Würzburg, Germany
| | - L. Schnetzler
- Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital of Frankfurt, Frankfurt, Germany
| | - H. Stopper
- Institute of Toxikology, University of Würzburg, Würzburg, Germany
| | - C. Jacob
- Department of Psychiatry and Psychotherapy, Hospital of Nürtingen, Nürtingen, Germany
| |
Collapse
|
25
|
Egberts K, Dang SY, Plener P, Romanos M, Gerlach M. Pharmacovigilance in children and adolescents with psychiatric disorders. Pharmacopsychiatry 2014. [DOI: 10.1055/s-0034-1386812] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
26
|
Dang SY, Jeutter V, Gerlach M, Romanos M, Taurines R, Egberts K. Aripiprazole induced extrapyramidal symptoms in two adolescents. Pharmacopsychiatry 2014. [DOI: 10.1055/s-0034-1386833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
27
|
Jarick I, Volckmar AL, Pütter C, Pechlivanis S, Nguyen TT, Dauvermann MR, Beck S, Albayrak Ö, Scherag S, Gilsbach S, Cichon S, Hoffmann P, Degenhardt F, Nöthen MM, Schreiber S, Wichmann HE, Jöckel KH, Heinrich J, Tiesler CMT, Faraone SV, Walitza S, Sinzig J, Freitag C, Meyer J, Herpertz-Dahlmann B, Lehmkuhl G, Renner TJ, Warnke A, Romanos M, Lesch KP, Reif A, Schimmelmann BG, Hebebrand J, Scherag A, Hinney A. Genome-wide analysis of rare copy number variations reveals PARK2 as a candidate gene for attention-deficit/hyperactivity disorder. Mol Psychiatry 2014; 19:115-21. [PMID: 23164820 PMCID: PMC3873032 DOI: 10.1038/mp.2012.161] [Citation(s) in RCA: 63] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/14/2011] [Revised: 09/21/2012] [Accepted: 10/09/2012] [Indexed: 12/12/2022]
Abstract
Attention-deficit/hyperactivity disorder (ADHD) is a common, highly heritable neurodevelopmental disorder. Genetic loci have not yet been identified by genome-wide association studies. Rare copy number variations (CNVs), such as chromosomal deletions or duplications, have been implicated in ADHD and other neurodevelopmental disorders. To identify rare (frequency ≤1%) CNVs that increase the risk of ADHD, we performed a whole-genome CNV analysis based on 489 young ADHD patients and 1285 adult population-based controls and identified one significantly associated CNV region. In tests for a global burden of large (>500 kb) rare CNVs, we observed a nonsignificant (P=0.271) 1.126-fold enriched rate of subjects carrying at least one such CNV in the group of ADHD cases. Locus-specific tests of association were used to assess if there were more rare CNVs in cases compared with controls. Detected CNVs, which were significantly enriched in the ADHD group, were validated by quantitative (q)PCR. Findings were replicated in an independent sample of 386 young patients with ADHD and 781 young population-based healthy controls. We identified rare CNVs within the parkinson protein 2 gene (PARK2) with a significantly higher prevalence in ADHD patients than in controls (P=2.8 × 10(-4) after empirical correction for genome-wide testing). In total, the PARK2 locus (chr 6: 162 659 756-162 767 019) harboured three deletions and nine duplications in the ADHD patients and two deletions and two duplications in the controls. By qPCR analysis, we validated 11 of the 12 CNVs in ADHD patients (P=1.2 × 10(-3) after empirical correction for genome-wide testing). In the replication sample, CNVs at the PARK2 locus were found in four additional ADHD patients and one additional control (P=4.3 × 10(-2)). Our results suggest that copy number variants at the PARK2 locus contribute to the genetic susceptibility of ADHD. Mutations and CNVs in PARK2 are known to be associated with Parkinson disease.
Collapse
Affiliation(s)
- I Jarick
- Institute of Medical Biometry and Epidemiology, University of Marburg, Marburg, Germany
| | - A-L Volckmar
- Department of Child and Adolescent Psychiatry, University of Duisburg-Essen, Essen, Germany
| | - C Pütter
- Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), University of Duisburg-Essen, Essen, Germany
| | - S Pechlivanis
- Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), University of Duisburg-Essen, Essen, Germany
| | - T T Nguyen
- Institute of Medical Biometry and Epidemiology, University of Marburg, Marburg, Germany
| | - M R Dauvermann
- Department of Child and Adolescent Psychiatry, University of Duisburg-Essen, Essen, Germany,University Hospital of Child and Adolescent Psychiatry, University of Bern, Bern, Switzerland
| | - S Beck
- Department of Child and Adolescent Psychiatry, University of Duisburg-Essen, Essen, Germany
| | - Ö Albayrak
- Department of Child and Adolescent Psychiatry, University of Duisburg-Essen, Essen, Germany
| | - S Scherag
- Department of Child and Adolescent Psychiatry, University of Duisburg-Essen, Essen, Germany
| | - S Gilsbach
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, RWTH Aachen University Clinics, Aachen, Germany
| | - S Cichon
- Institute of Neuroscience and Medicine (INM-1), Structural and Functional Organization of the Brain, Genomic Imaging, Research Center Juelich, Juelich, Germany,Institute of Human Genetics, University of Bonn, Bonn, Germany,Deptartment of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany
| | - P Hoffmann
- Institute of Human Genetics, University of Bonn, Bonn, Germany,Deptartment of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany
| | - F Degenhardt
- Institute of Human Genetics, University of Bonn, Bonn, Germany,Deptartment of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany
| | - M M Nöthen
- Institute of Human Genetics, University of Bonn, Bonn, Germany,Deptartment of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany,German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
| | - S Schreiber
- Institute of Clinical Molecular Biology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - H-E Wichmann
- Institute of Epidemiology, German Research Center for Environmental Health, Helmholtz Center Munich, Neuherberg, Germany
| | - K-H Jöckel
- Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), University of Duisburg-Essen, Essen, Germany
| | - J Heinrich
- Institute of Epidemiology, German Research Center for Environmental Health, Helmholtz Center Munich, Neuherberg, Germany
| | - C M T Tiesler
- Institute of Epidemiology, German Research Center for Environmental Health, Helmholtz Center Munich, Neuherberg, Germany,Division of Metabolic Diseases and Nutritional Medicine, Dr von Hauner Children's Hospital, Ludwig-Maximilians-University of Munich, Munich, Germany
| | - S V Faraone
- Departments of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, NY, USA
| | - S Walitza
- Department of Child and Adolescent Psychiatry, University of Zurich, Zurich, Switzerland
| | - J Sinzig
- Department for Child and Adolescent Psychiatry, University of Cologne, Cologne, Germany,Department for Child and Adolescent Psychiatry and Psychotherapy, LVR—clinic Bonn, Bonn, Germany
| | - C Freitag
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, JW Goethe-Universität Frankfurt am Main, Frankfurt am Main, Germany
| | - J Meyer
- Department of Neurobehavioral Genetics, Institute of Psychobiology, University of Trier, Trier, Germany
| | - B Herpertz-Dahlmann
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, RWTH Aachen University Clinics, Aachen, Germany
| | - G Lehmkuhl
- Department for Child and Adolescent Psychiatry, University of Cologne, Cologne, Germany
| | - T J Renner
- Department of Child and Adolescent Psychiatry, University of Wuerzburg, Wuerzburg, Germany
| | - A Warnke
- Department of Child and Adolescent Psychiatry, University of Wuerzburg, Wuerzburg, Germany
| | - M Romanos
- Department of Child and Adolescent Psychiatry, University of Wuerzburg, Wuerzburg, Germany,Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Munich, Munich, Germany
| | - K-P Lesch
- Department of Psychiatry, Psychosomatics and Psychotherapy, Division of Molecular Psychiatry, ADHD Clinical Research Network, Laboratory of Translational Neuroscience, University of Wuerzburg, Wuerzburg, Germany,Department of Neuroscience, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands
| | - A Reif
- Department of Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Wuerzburg, Germany
| | - B G Schimmelmann
- Department of Child and Adolescent Psychiatry, University of Duisburg-Essen, Essen, Germany,University Hospital of Child and Adolescent Psychiatry, University of Bern, Bern, Switzerland
| | - J Hebebrand
- Department of Child and Adolescent Psychiatry, University of Duisburg-Essen, Essen, Germany
| | - A Scherag
- Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), University of Duisburg-Essen, Essen, Germany
| | - A Hinney
- Department of Child and Adolescent Psychiatry, University of Duisburg-Essen, Essen, Germany,Department of Child and Adolescent Psychiatry, University of Dusiburg-Essen, Virchowstraße 174, D-45147 Essen, Germany. E-mail:
| |
Collapse
|
28
|
Kohlboeck G, Romanos M, Tiesler C, Koletzko S, Kratzsch J, Thiery J, Bauer CP, von Berg A, Berdel D, Hoffmann B, Schaaf B, Lehmann I, Herbarth O, Heinrich J. Peer problems are associated with elevated serum leptin levels in children. Psychol Med 2014; 44:255-265. [PMID: 23561045 DOI: 10.1017/s003329171300069x] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
BACKGROUND Leptin is thought to act as an important mediator in stress reactions. To date, no study has examined the association between psychological stress and leptin levels in children. This study aimed to assess the association between emotional symptoms and peer problems and serum leptin levels in children aged 10 years of the two population-based GINI-plus and LISA-plus birth cohorts. METHOD Cross-sectional data from 2827 children aged 10 years were assessed with regard to leptin concentrations in serum and behavioral problems using the parent-reported Strengths and Difficulties Questionnaire (SDQ). Linear regression modeling was applied to determine the likelihood of elevated leptin levels in children with emotional symptoms and peer problems, controlling for socio-economic status (SES), body mass index (BMI), fasting serum leptin levels, pubertal development and sex hormones. RESULTS We found that increases in emotional symptoms (exp β adj = 1.03, s.e. = 0.02, p < 0.04) and peer problems (exp β adj = 1.05, s.e. = 0.01, p = 0.0001) were significantly associated with higher serum leptin levels controlled for BMI and sociodemographic factors. Similar results were found when the fasting serum leptin sample was examined (exp β adj = 1.08, s.e. = 0.04, p = 0.0294). Gender-stratified analyses showed a significant relationship between serum leptin and peer problems in girls (exp β adj = 1.05, s.e. = 0.02, p = 0.03), and a borderline significant association in boys (exp β adj = 1.04, s.e. = 0.02, p = 0.05). CONCLUSIONS Children with peer problems have higher stress and eat more, acquire a higher body fat mass and thus, through increased leptin resistance, exhibit higher leptin levels.
Collapse
Affiliation(s)
- G Kohlboeck
- Helmholtz Zentrum Muenchen, German Research Center for Environmental Health, Institute of Epidemiology I, Neuherberg, Germany
| | - M Romanos
- Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital Wuerzburg, Germany
| | - C Tiesler
- Helmholtz Zentrum Muenchen, German Research Center for Environmental Health, Institute of Epidemiology I, Neuherberg, Germany
| | - S Koletzko
- Dr von Hauner Children's Hospital, Ludwig-Maximilians-University of Munich, Germany
| | - J Kratzsch
- University Leipzig, Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, Germany
| | - J Thiery
- University Leipzig, Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, Germany
| | - C-P Bauer
- Department of Pediatrics, Technical University of Munich, Germany
| | - A von Berg
- Department of Pediatrics, Marien-Hospital Wesel, Germany
| | - D Berdel
- Department of Pediatrics, Marien-Hospital Wesel, Germany
| | - B Hoffmann
- Leibniz Research Institute for Environmental Medicine, University of Düsseldorf, Germany
| | - B Schaaf
- Medical Practice for Pediatrics, Bad Honnef, Germany
| | - I Lehmann
- UFZ-Center for Environmental Research, Leipzig, Germany
| | - O Herbarth
- University Leipzig, Faculty of Medicine, Environmental Medicine and Hygiene, Leipzig, Germany
| | - J Heinrich
- Helmholtz Zentrum Muenchen, German Research Center for Environmental Health, Institute of Epidemiology I, Neuherberg, Germany
| |
Collapse
|
29
|
Schimmelmann BG, Hinney A, Scherag A, Pütter C, Pechlivanis S, Cichon S, Jöckel KH, Schreiber S, Wichmann HE, Albayrak Ö, Dauvermann M, Konrad K, Wilhelm C, Herpertz-Dahlmann B, Lehmkuhl G, Sinzig J, Renner TJ, Romanos M, Warnke A, Lesch KP, Reif A, Hebebrand J. Bipolar disorder risk alleles in children with ADHD. J Neural Transm (Vienna) 2013; 120:1611-7. [DOI: 10.1007/s00702-013-1035-8] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2012] [Accepted: 05/10/2013] [Indexed: 11/28/2022]
|
30
|
Buske-Kirschbaum A, Schmitt J, Plessow F, Romanos M, Weidinger S, Roessner V. Psychoendocrine and psychoneuroimmunological mechanisms in the comorbidity of atopic eczema and attention deficit/hyperactivity disorder. Psychoneuroendocrinology 2013; 38:12-23. [PMID: 23141851 DOI: 10.1016/j.psyneuen.2012.09.017] [Citation(s) in RCA: 116] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/20/2012] [Revised: 09/24/2012] [Accepted: 09/27/2012] [Indexed: 12/19/2022]
Abstract
Epidemiological data indicate that atopic eczema (AE) in infancy significantly increases the risk for attention deficit/hyperactivity disorder (ADHD) in later life. The underlying pathophysiological mechanisms of this comorbidity are unknown. We propose that the release of inflammatory cytokines caused by the allergic inflammation and/or elevated levels of psychological stress as a result of the chronic disease interfere with the maturation of prefrontal cortex regions and neurotransmitter systems involved ADHD pathology. Alternatively, increased stress levels in ADHD patients may trigger AE via neuroimmunological mechanisms. In a third model, AE and ADHD may be viewed as two separate disorders with one or more shared risk factors (e.g., genetics, prenatal stress) that increase the susceptibility for both disorders leading to the co-occurrence of AE and ADHD. Future investigation of these three models may lead to a better understanding of the mechanisms underlying the observed comorbidity between AE and ADHD and further, to targeted interdisciplinary primary prevention and treatment strategies.
Collapse
Affiliation(s)
- A Buske-Kirschbaum
- Department of Biopsychology, Technical University of Dresden, Dresden, Germany.
| | | | | | | | | | | |
Collapse
|
31
|
Jain M, Vélez JI, Acosta MT, Palacio LG, Balog J, Roessler E, Pineda D, Londoño AC, Palacio JD, Arbelaez A, Lopera F, Elia J, Hakonarson H, Seitz C, Freitag CM, Palmason H, Meyer J, Romanos M, Walitza S, Hemminger U, Warnke A, Romanos J, Renner T, Jacob C, Lesch KP, Swanson J, Castellanos FX, Bailey-Wilson JE, Arcos-Burgos M, Muenke M. A cooperative interaction between LPHN3 and 11q doubles the risk for ADHD. Mol Psychiatry 2012; 17:741-7. [PMID: 21606926 PMCID: PMC3382263 DOI: 10.1038/mp.2011.59] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
In previous studies of a genetic isolate, we identified significant linkage of attention deficit hyperactivity disorder (ADHD) to 4q, 5q, 8q, 11q and 17p. The existence of unique large size families linked to multiple regions, and the fact that these families came from an isolated population, we hypothesized that two-locus interaction contributions to ADHD were plausible. Several analytical models converged to show significant interaction between 4q and 11q (P<1 × 10(-8)) and 11q and 17p (P<1 × 10(-6)). As we have identified that common variants of the LPHN3 gene were responsible for the 4q linkage signal, we focused on 4q-11q interaction to determine that single-nucleotide polymorphisms (SNPs) harbored in the LPHN3 gene interact with SNPs spanning the 11q region that contains DRD2 and NCAM1 genes, to double the risk of developing ADHD. This interaction not only explains genetic effects much better than taking each of these loci effects by separated but also differences in brain metabolism as depicted by proton magnetic resonance spectroscopy data and pharmacogenetic response to stimulant medication. These findings not only add information about how high order genetic interactions might be implicated in conferring susceptibility to develop ADHD but also show that future studies of the effects of genetic interactions on ADHD clinical information will help to shape predictive models of individual outcome.
Collapse
Affiliation(s)
- M Jain
- Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - J I Vélez
- Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - M T Acosta
- Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - L G Palacio
- Neurosciences Group, University of Antioquia, Medellín, Colombia
| | - J Balog
- Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - E Roessler
- Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - D Pineda
- Neurosciences Group, University of Antioquia, Medellín, Colombia
| | - A C Londoño
- Neurosciences Group, University of Antioquia, Medellín, Colombia
| | - J D Palacio
- Neurosciences Group, University of Antioquia, Medellín, Colombia
| | - A Arbelaez
- Neurosciences Group, University of Antioquia, Medellín, Colombia
| | - F Lopera
- Neurosciences Group, University of Antioquia, Medellín, Colombia
| | - J Elia
- The Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - H Hakonarson
- The Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - C Seitz
- Department of Child and Adolescent Psychiatry, Saarland University Hospital, Homburg, Saar, Germany
| | - C M Freitag
- Department of Child and Adolescent Psychiatry, Saarland University Hospital, Homburg, Saar, Germany
| | - H Palmason
- Graduate School for Psychobiology, Division of Neuro-Behavioral Genetics, University of Trier, Trier, Germany
| | - J Meyer
- Graduate School for Psychobiology, Division of Neuro-Behavioral Genetics, University of Trier, Trier, Germany
| | - M Romanos
- Department of Child and Adolescent Psychiatry and Psychotherapy, University of Würzburg, Würzburg, Germany
| | - S Walitza
- Department of Child and Adolescent Psychiatry and Psychotherapy, University of Würzburg, Würzburg, Germany
| | - U Hemminger
- Department of Child and Adolescent Psychiatry and Psychotherapy, University of Würzburg, Würzburg, Germany
| | - A Warnke
- Department of Child and Adolescent Psychiatry and Psychotherapy, University of Würzburg, Würzburg, Germany
| | - J Romanos
- Department of Psychiatry and Psychotherapy, University of Würzburg, Würzburg, Germany
| | - T Renner
- Department of Child and Adolescent Psychiatry and Psychotherapy, University of Würzburg, Würzburg, Germany,Department of Psychiatry and Psychotherapy, University of Würzburg, Würzburg, Germany,Molecular and Psychobiology, University of Würzburg, Würzburg, Germany
| | - C Jacob
- Department of Psychiatry and Psychotherapy, University of Würzburg, Würzburg, Germany
| | - K-P Lesch
- Department of Child and Adolescent Psychiatry and Psychotherapy, University of Würzburg, Würzburg, Germany,Department of Psychiatry and Psychotherapy, University of Würzburg, Würzburg, Germany,Molecular and Psychobiology, University of Würzburg, Würzburg, Germany
| | - J Swanson
- UCI Child Development Center, University of California, Irvine, CA, USA
| | | | - J E Bailey-Wilson
- Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - M Arcos-Burgos
- Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA,Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Building 35, Room 1B-209, Bethesda, MD 20892-3717, USA. E-mails: and
| | - M Muenke
- Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA,Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Building 35, Room 1B-209, Bethesda, MD 20892-3717, USA. E-mails: and
| |
Collapse
|
32
|
Romanos M, Buske-Kirschbaum A, Fölster-Holst R, Gerlach M, Weidinger S, Schmitt J. Itches and scratches – is there a link between eczema, ADHD, sleep disruption and food hypersensitivity? Allergy 2011; 66:1407-9. [PMID: 21895691 DOI: 10.1111/j.1398-9995.2011.02705.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
|
33
|
Schmitt J, Romanos M, Apfelbacher C. Komorbidität von Neurodermitis und Aufmerksamkeits-Defizit/Hyperaktivitäts-Syndrom: Meta-Analyse aktueller populationsbezogener Studien aus Deutschland. Gesundheitswesen 2011. [DOI: 10.1055/s-0031-1283610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
34
|
Schmitt J, Chen CM, Apfelbacher C, Romanos M, Lehmann I, Herbarth O, Schaaf B, Kraemer U, von Berg A, Wichmann HE, Heinrich J. Infant eczema, infant sleeping problems, and mental health at 10 years of age: the prospective birth cohort study LISAplus. Allergy 2011; 66:404-11. [PMID: 21029113 DOI: 10.1111/j.1398-9995.2010.02487.x] [Citation(s) in RCA: 92] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
BACKGROUND Cross-sectional studies suggest an association between eczema and mental health problems, possibly modified by sleeping problems, but prospective evidence is missing. We aimed to prospectively investigate the relationship between infant eczema (within first 2 years of age), infant sleeping problems (within first 2 years of age), and the risk of mental health problems at 10 years of age. METHODS Between 1997 and 1999, a population-based birth cohort was recruited in Munich, Leipzig, Wesel, and Bad Honnef, Germany, and followed until 10 years of age. Physician-diagnosed eczema, parent-reported sleeping problems, and known environmental risk factors for atopy were regularly assessed until 10 years of age. Mental health was measured using the Strengths and Difficulties Questionnaire (parent version) at 10 years of age. We applied logistic regression modeling adjusting for environmental and lifestyle factors, allergic comorbidity, and family history of eczema. RESULTS From the original cohort of 3097 neonates, 1658 (54%) were followed until age 10, while 1578 (51%) were eligible for analysis. In the fully adjusted model, children with infant eczema were at increased risk of hyperactivity/inattention at 10 years of age [odds ratio (OR) 1.78; 95% confidence interval (95% CI) 1.02-3.09]. Infant eczema with concurrent sleeping problems predicted emotional problems [OR 2.63; 95% confidence interval (95% CI) 1.20-5.76] and conduct problems (OR 3.03; 95% CI 1.01-9.12) at 10 years of age. CONCLUSIONS Infant eczema with concurrent sleeping problems appears to be a risk factor for the development of mental health problems.
Collapse
Affiliation(s)
- J Schmitt
- Department of Dermatology, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
|
36
|
Schimmelmann BG, Friedel S, Nguyen TT, Sauer S, Ganz Vogel CI, Konrad K, Wilhelm C, Sinzig J, Renner TJ, Romanos M, Palmason H, Dempfle A, Walitza S, Freitag C, Meyer J, Linder M, Schäfer H, Warnke A, Lesch KP, Herpertz-Dahlman B, Hinney A, Hebebrand J. Exploring the genetic link between RLS and ADHD. J Psychiatr Res 2009; 43:941-5. [PMID: 19223043 DOI: 10.1016/j.jpsychires.2009.01.003] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/19/2008] [Revised: 01/13/2009] [Accepted: 01/13/2009] [Indexed: 01/27/2023]
Abstract
Attention deficit/hyperactivity disorder (ADHD) is a highly heritable neurodevelopmental disorder of childhood onset. Clinical and biological evidence points to shared common central nervous system (CNS) pathology of ADHD and restless legs syndrome (RLS). It was hypothesized that variants previously found to be associated with RLS in two large genome-wide association studies (GWA), will also be associated with ADHD. SNPs located in MEIS1 (rs2300478), BTBD9 (rs9296249, rs3923809, rs6923737), and MAP2K5 (rs12593813, rs4489954) as well as three SNPs tagging the identified haplotype in MEIS1 (rs6710341, rs12469063, rs4544423) were genotyped in a well characterized German sample of 224 families comprising one or more affected sibs (386 children) and both parents. We found no evidence for preferential transmission of the hypothesized variants to ADHD. Subsequent analyses elicited nominal significant association with haplotypes consisting of the three SNPs in BTBD9 (chi2 = 14.8, df = 7, nominal p = 0.039). According to exploratory post hoc analyses, the major contribution to this finding came from the A-A-A-haplotype with a haplotype-wise nominal p-value of 0.009. However, this result did not withstand correction for multiple testing. In view of our results, RLS risk alleles may have a lower effect on ADHD than on RLS or may not be involved in ADHD. The negative findings may additionally result from genetic heterogeneity of ADHD, i.e. risk alleles for RLS may only be relevant for certain subtypes of ADHD. Genes relevant to RLS remain interesting candidates for ADHD; particularly BTBD9 needs further study, as it has been related to iron storage, a potential pathophysiological link between RLS and certain subtypes of ADHD.
Collapse
Affiliation(s)
- B G Schimmelmann
- Department of Child and Adolescent Psychiatry and Psychotherapy, University of Duisburg-Essen, LVR Klinikun Essen, Virchowstr. 174, 45147 Essen, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Schwenck C, Schmiedeler S, Zenglein Y, Renner T, Romanos M, Jans T, Schneider W, Warnke A. Reflective and impulsive reactions in ADHD subtypes. ACTA ACUST UNITED AC 2009; 1:3-10. [DOI: 10.1007/s12402-009-0002-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2008] [Accepted: 03/18/2009] [Indexed: 11/28/2022]
|
38
|
Romanos M, Schwenck C, Walitza S. Diagnostik der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung im Kindes- und Jugendalter. Nervenarzt 2008; 79:782-90. [DOI: 10.1007/s00115-008-2511-5] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
39
|
Romanos M, Freitag C, Jacob C, Craig DW, Dempfle A, Nguyen TT, Halperin R, Walitza S, Renner TJ, Seitz C, Romanos J, Palmason H, Reif A, Heine M, Windemuth-Kieselbach C, Vogler C, Sigmund J, Warnke A, Schäfer H, Meyer J, Stephan DA, Lesch KP. Genome-wide linkage analysis of ADHD using high-density SNP arrays: novel loci at 5q13.1 and 14q12. Mol Psychiatry 2008; 13:522-30. [PMID: 18301393 DOI: 10.1038/mp.2008.12] [Citation(s) in RCA: 91] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Previous genome-wide linkage studies applied the affected sib-pair design; one investigated extended pedigrees of a genetic isolate. Here, results of a genome-wide high-density linkage scan of attention-deficit/hyperactivity disorder (ADHD) using an array-based genotyping of approximately 50 K single nucleotide polymorphism (SNPs) markers are presented. We investigated eight extended pedigrees of German origin that were non-related, not part of a genetic isolate and ascertained on the basis of clinical referral. Two parametric analyses maximizing LOD scores (MOD) and a non-parametric analysis for both a broad and a narrow phenotype approach were conducted. Novel linkage loci across all families were detected at 2q35, 5q13.1, 6q22-23 and 14q12, within individual families at 18q11.2-12.3. Further linkage regions at 7q21.11, 9q22 and 16q24.1 in all families, and at 1q25.1, 1q25.3, 9q31.1-33.1, 9q33, 12p13.33, 15q11.2-13.3 and 16p12.3-12.2 in individual families replicate previous findings. High-resolution linkage mapping points to several novel candidate genes characterized by dense expression in the brain and potential impact on disorder-relevant synaptic transmission. Our study provides further evidence for common gene effects throughout different populations despite the complex multifactorial etiology of ADHD.
Collapse
Affiliation(s)
- M Romanos
- ADHD Clinical Research Program, Department of Child and Adolescent Psychiatry and Psychotherapy, University of Wuerzburg, Wuerzburg, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Friedel S, Saar K, Sauer S, Dempfle A, Walitza S, Renner T, Romanos M, Freitag C, Seitz C, Palmason H, Scherag A, Windemuth-Kieselbach C, Schimmelmann BG, Wewetzer C, Meyer J, Warnke A, Lesch KP, Reinhardt R, Herpertz-Dahlmann B, Linder M, Hinney A, Remschmidt H, Schäfer H, Konrad K, Hübner N, Hebebrand J. Association and linkage of allelic variants of the dopamine transporter gene in ADHD. Mol Psychiatry 2007; 12:923-33. [PMID: 17579611 DOI: 10.1038/sj.mp.4001986] [Citation(s) in RCA: 70] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Previously, we had reported a genome-wide scan for attention-deficit/hyperactivity disorder (ADHD) in 102 families with affected sibs of German ancestry; the highest multipoint LOD score of 4.75 was obtained on chromosome 5p13 (parametric HLOD analysis under a dominant model) near the dopamine transporter gene (DAT1). We genotyped 30 single nucleotide polymorphisms (SNPs) in this candidate gene and its 5' region in 329 families (including the 102 initial families) with 523 affected offspring. We found that (1) SNP rs463379 was significantly associated with ADHD upon correction for multiple testing (P=0.0046); (2) the global P-value for association of haplotypes was significant for block two upon correction for all (n=3) tested blocks (P=0.0048); (3) within block two we detected a nominal P=0.000034 for one specific marker combination. This CGC haplotype showed relative risks of 1.95 and 2.43 for heterozygous and homozygous carriers, respectively; and (4) finally, our linkage data and the genotype-IBD sharing test (GIST) suggest that genetic variation at the DAT1 locus explains our linkage peak and that rs463379 (P<0.05) is the only SNP of the above haplotype that contributed to the linkage signal. In sum, we have accumulated evidence that genetic variation at the DAT1 locus underlies our ADHD linkage peak on chromosome 5; additionally solid association for a single SNP and a haplotype were shown. Future studies are required to assess if variation at this locus also explains other positive linkage results obtained for chromosome 5p.
Collapse
Affiliation(s)
- S Friedel
- Department of Child and Adolescent Psychiatry, University of Duisburg-Essen, Essen, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Röser C, Renner TJ, Walitza S, Dempfle A, Nguyen T, Romanos M, Jacob C, Reif A, Schäfer H, Gerlach M, Warnke A, Lesch KP. GIRK2 – A novel candidate gene for attention deficit hyperactivity disorder. Pharmacopsychiatry 2007. [DOI: 10.1055/s-2007-991831] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
42
|
Schimmelmann BG, Friedel S, Dempfle A, Warnke A, Lesch KP, Walitza S, Renner TJ, Romanos M, Herpertz-Dahlmann B, Linder M, Schäfer H, Seitz C, Palmason H, Freitag C, Meyer J, Konrad K, Hinney A, Hebebrand J. No evidence for preferential transmission of common valine allele of the Val66Met polymorphism of the brain-derived neurotrophic factor gene (BDNF) in ADHD. J Neural Transm (Vienna) 2007; 114:523-6. [PMID: 17219016 DOI: 10.1007/s00702-006-0616-1] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2006] [Accepted: 12/04/2006] [Indexed: 12/01/2022]
Abstract
Attention deficit/hyperactivity disorder (ADHD) is a highly heritable common neurodevelopmental disorder with onset in childhood. A coding SNP (rs6265, Val66Met) of the brain-derived neurotrophic factor gene (BDNF) has recently been associated with ADHD. More specifically, paternal over-transmission of the common Val66 allele to affected children had been observed. We aimed to confirm these findings in a large, sufficiently powered, and well characterized German ADHD family sample. The Val66Met polymorphism of BDNF was genotyped in 294 families comprising one or more affected sibs (468 children). Contrary to previous reports, we did not observe over-transmission of the common Val66 allele, from either parent to affected children. We did not find support for an involvement of the Val66 allele of the Val66Met polymorphism of BDNF in the pathogenesis of ADHD in our sample.
Collapse
Affiliation(s)
- B G Schimmelmann
- Department of Child and Adolescent Psychiatry, Rheinische Kliniken Essen, University of Duisburg-Essen, Essen, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Abstract
1. The S. cerevisiae alpha-factor prepro leader is functional and is correctly processed in P. pastoris. 2. P. pastoris has a high secretory capacity, but yields can be severely reduced by extracellular proteases. This problem can be reduced by altering the medium composition, e.g., adjusting the pH or by adding casamino acids. 3. A rapid DNA dot-blot technique can be used for mass screening of transformants to obtain high-copy-number, high-expressing strains. 4. For mEGF, which is an efficiently secreted protein, there was a good correlation between gene dosage and yield, and maximum levels were obtained at high copy number. 5. Vectors conferring resistance to G418 have been developed for the selection of high-copy-number transformants. These vectors can also be used to isolate a series of transformants with increasing copy number of optimizing the expression of genes where high copy number may be detrimental. 6. The HIV-1 ENV gene was not expressed in P. pastoris owing to fortuitous termination of transcription within AT-rich regions. This is a species-specific phenomenon, since full-length HIV-1 ENV transcripts are produced in S. cerevisiae. The problem was overcome by synthesizing the relevent portion of the gene with increased GC content. 7. ENV was hyperglycosylated and immunologically inactive when secreted by P. pastoris. The yield was reduced by extracellular proteases, but like mEGF, this could be significantly improved by altering the pH of the culture medium and by adding casamino acids. 8. In single-copy integrants, transcripts from the semisynthetic HIV-1 ENV gene were almost as abundant as endogenous AOX1. Transcript levels increased progressively with increasing copy number, showing that the AOX1 promoter is not greatly limited by the level of trans-activating factors.
Collapse
Affiliation(s)
- J Clare
- Department of Food Science and Technology, University of Nebraska, Lincoln, NE
| | | | | | | |
Collapse
|
44
|
Affiliation(s)
- M Romanos
- Medicines Research Centre, Glaxo-Wellcome, Stevenage, UK
| | | | | | | |
Collapse
|
45
|
Abstract
1. The yield of fragment C was only modestly affected by Mut phenotype, and the site and type of integration event. 2. Fragment C accumulation was closely correlated with gene dosage and maximal expression levels required high gene copy number. 3. Yields were greatly increased in controlled fermenters, compared to shake-flasks, owing to the high cell density achieved and to an increased efficiency of induction (2.5- to 10-fold). 4. In fermenter inductions of a 14-copy strain, fragment C accumulated to 27% of total protein, giving an estimated yield of 12 g/L. 5. Considerable clonal variation in the level of expression occurred with transplacement transformants, and this was owing to a diversity of different integration events and to differences in gene copy number. 6. These multicopy transplacement events occur by in vivo circularization of transforming DNA fragments followed by repeated single-crossover integration. This is presumably a general phenomenon, such that it should be possible to obtain multicopy integrants from all P. pastoris transplacement transformations.
Collapse
Affiliation(s)
- J Clare
- Medicines Research Centre, Glaxo-Wellcome, Stevenage, UK
| | | | | |
Collapse
|
46
|
Williamson AR, Dykes CW, Romanos M, Bailey D. Human genome project Europe. Trends Pharmacol Sci 1997; 18:303-5. [PMID: 9345844] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
47
|
Piccini A, Storey A, Romanos M, Banks L. Regulation of human papillomavirus type 16 DNA replication by E2, glucocorticoid hormone and epidermal growth factor. J Gen Virol 1997; 78 ( Pt 8):1963-70. [PMID: 9266995 DOI: 10.1099/0022-1317-78-8-1963] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
The E1 and E2 proteins are the only human papillomavirus (HPV) proteins required for transient replication of plasmids containing the viral origin. The E2 gene products play key roles in both viral transcription and replication. In this study we have analysed in further detail the nature of the association between E1 and E2 using a series of E2 proteins mutated in conserved regions of the N-terminal domain. These proteins were tested for their ability to activate transcription and to stimulate viral DNA replication. Several of these mutants revealed that the two functions of E2 can be separated, and that they define three widely spaced regions of the N-terminal domain which are important for DNA replication, two of which retain E1-binding activity. This suggests that E2 may have a role in viral DNA replication other than simply localizing E1 to the origin of replication. Additional important elements for regulating viral gene expression have been shown to be glucocorticoid hormones and epidermal growth factor (EGF). We show here that they may also be involved in regulating viral DNA replication. Our studies show that the addition of glucocorticoid hormone significantly stimulates viral DNA replication. In contrast, addition of EGF results in modest repression of viral DNA replication. These results have important implications for the pathogenesis of HPV infection and suggest that the relative levels of E2, glucocorticoid hormone and EGF may significantly affect the outcome of an HPV infection.
Collapse
Affiliation(s)
- A Piccini
- International Centre for Genetic Engineering and Biotechnology, AREA Science Park, Trieste, Italy
| | | | | | | |
Collapse
|
48
|
Charles IG, Li JL, Roberts M, Beesley K, Romanos M, Pickard DJ, Francis M, Campbell D, Dougan G, Brennan MJ. Identification and characterization of a protective immunodominant B cell epitope of pertactin (P.69) from Bordetella pertussis. Eur J Immunol 1991; 21:1147-53. [PMID: 1709865 DOI: 10.1002/eji.1830210509] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Epitopes defined by monoclonal antibodies (mAb) specific for the Bordetella pertussis outer membrane protein P.69 (pertactin) were mapped using a series of amino- and carboxy-terminal deletion mutants expressed in Escherichia coli. mAb were found to bind predominantly to a region of pertactin spanning a (Pro-Gln-Pro)5 repeat motif and one mAb was found to bind to another region spanning a (Gly-Gly-Xaa-Xaa-Pro)5 repeat motif. To localize further the mAb-binding sites, a panel of synthetic peptides, a series of 94 overlapping hexameric peptides, and a P.69 30-amino acid fusion to a hepatitis B core protein (HBcAg-69), were synthesized. This combined approach has identified the binding site for the mAb BBO5: Pro-Gly-Pro-Gln-Pro-Pro; mAb BBO7, E4A8 and E4D7: Ala-Pro-Gln-Pro-Pro-Ala-Gly-Arg; and mAb BPE3: Thr-Leu-Trp-Tyr-Ala-Glu-Ser-Asn-Ala-Leu-Ser-Lys-Arg. We have used a non-lethal murine respiratory model of B. pertussis infection to investigate the ability of a peptide containing the epitope of the mAb BBO5 to elicit protective immunity. Immunization of mice with the HBcAg-69 protein prevented growth of B. pertussis in the lungs compared to mice receiving HBcAg alone, and protection correlated with high titers of anti-P.69 antibodies.
Collapse
Affiliation(s)
- I G Charles
- Department of Molecular Biology, Wellcome Biotech, Beckenham, Kent, GB
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Wakelin LP, Romanos M, Chen TK, Glaubiger D, Canellakis ES, Waring MJ. Structural limitations on the bifunctional intercalation of diacridines into DNA. Biochemistry 1978; 17:5057-63. [PMID: 568937 DOI: 10.1021/bi00616a031] [Citation(s) in RCA: 95] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
An homologous series of diacridines containing two 9-aminoacridine chromophores linked via a simple methylene chain has been studied in order to investigate the minimum interchromophore separation required to permit bifunctional intercalation. Viscometric, sedimentation, and electric dichroism experiments show that compounds having one to four methylene groups in the linker are restricted to monofunctional intercalation, whereas the interaction becomes bifunctional when the chain length is increased to six carbons or more. The results indicate that bifunctional reaction occurs with an interchromophore distance not exceeding 8.8 A, implying that intercalation by these compounds is not subject to neighbor exclusion if the mode of binding is of the classical intercalation type.
Collapse
|